Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives
- 133 Downloads
Purpose and Methods
Patients with inoperable and metastasized neuroendocrine tumors (NETs), particularly those with grades 1 and 2, usually receive treatment with somatostatin analogues (SSAs). Peptide receptor radionuclide therapy (PRRT) has gained momentum over the past two decades in patients who progress on SSAs. 177Lu-DOTATATE is currently the most widely used radiopeptide for PRRT. We reviewed the recent evidence on PRRT and the treatment of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
177Lu-DOTATATE can be used as neoadjuvant treatment in patients with inoperable GEP-NETs, who might be candidate for surgery after treatment and as adjuvant therapy after surgical intervention. Combination treatments of PRRT with chemotherapy or targeted agents as well as combinations of radionuclides in patients with NETs have been explored over the last few years. The majority of patients with NETs experience partial response or have disease stabilization, a small percentage has complete response, while some 30% of patients, however, will have disease progression. The safety and efficacy of retreatment with extra cycles of PRRT as salvage therapy have been evaluated in small retrospective series.
Overall, there is evidence that disease control and quality of life improve significantly after 117Lu PRRT therapy. Clinical trials on this therapy are scarce, and there is a need for further studies to establish proper management guidelines.
KeywordsNuclear medicine Theranostics Lutetium Neuroendocrine tumors Peptide receptor radionuclide therapy
Compliance with Ethical Standards
Conflict of Interest
Nader Hirmas, Raya Jadaan, and Akram Al-Ibraheem declare no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Klimstra DS, Yang Z. Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system. Waltham: UpToDate; 2013.Google Scholar
- 20.Waldherr C, Maecke HR, Schumacher T, Schirp U, Forrer F, Nitzsche EU, et al. How does tumor response depend on the number of treatment sessions at constant injected dose using Y-90-DOTATOC in neuroendocrine tumors? J Nucl Med. 2002;43:315.Google Scholar
- 21.Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [90 Y-DOTA 0, Tyr 3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147–56.CrossRefPubMedGoogle Scholar
- 23.Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Müller-Brand J, Bruun KH, et al. Peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology. 2011;93:189–96.CrossRefPubMedGoogle Scholar
- 24.Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2009;21:787–94.CrossRefPubMedGoogle Scholar
- 25.Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, De Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3] octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417–22.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Brabander T, Van der Zwan WA, Teunissen JJ, Kam BL, Feelders RA, de Herder WW, et al. Long-term efficacy, survival and safety of [177Lu-DOTA0, Tyr3] octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617–24. clincanres-2743CrossRefPubMedGoogle Scholar
- 30.Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788–97.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Ashwathanarayana AG, Biswal CK, Sood A, Parihar AS, Kapoor R, Mittal BR. Image guided combination of 177Lu-DOTATATE and capecitabine peptide receptor chemoradionuclide therapy in metastatic mediastinal paraganglioma. J Nucl Med Technol. 2017; https://doi.org/10.2967/jnmt.117.197400.
- 33.van Essen M, Krenning EP, Kam BL, de Herder WW, van Aken MO, Kwekkeboom DJ. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:743–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Ballal S, Yadav MP, Damle NA, Sahoo RK, Bal C. Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumors: a long-term-outcome, toxicity, survival, and quality-of-life study. Clin Nucl Med. 2017; https://doi.org/10.1097/RLU.0000000000001816.
- 39.Perysinakis I, Aggeli C, Kaltsas G, Zografos GN. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality. Hormones (Athens). 2016;15:15–22.Google Scholar
- 42.Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefańska A, Tomaszuk M, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011;38:1669–74.CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Bertani E, Fazio N, Radice D, Zardini C, Grana C, Bodei L, et al. Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1–G2 pancreatic neuroendocrine tumors with unresectable liver metastases. Ann Surg Oncol. 2016;23:981–9.CrossRefPubMedGoogle Scholar
- 55.Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56.CrossRefPubMedGoogle Scholar
- 60.Swärd C, Bernhardt P, Ahlman H, Wängberg B, Forssell-Aronsson E, Larsson M, et al. [177Lu-DOTA0-Tyr3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J Surg. 2010;34:1368–72.CrossRefPubMedGoogle Scholar
- 67.Kong G, Thompson M, Collins M, Herschtal A, Hofman MS, Johnston V, et al. Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). Eur J Nucl Med Mol Imaging. 2014;41:1831–44.CrossRefPubMedPubMedCentralGoogle Scholar
- 68.Kong G, Callahan J, Hofman MS, Pattison DA, Akhurst T, Michael M, et al. High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2017;44:476–89.CrossRefPubMedGoogle Scholar